The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: results from a randomized phase 3 trial.

In kidney transplant recipients, delayed graft function (DGF) increases the risk of graft failure and mortality. In a phase 3, randomized, double-blind, placebo-controlled trial, we investigated the hepatocyte growth factor mimetic, ANG-3777 (once daily for 3 consecutive days, starting ≤30 hours posttransplant), in 248 patients receiving a first kidney transplant from a deceased donor. At day 360, estimated glomerular filtration rate (eGFR; primary endpoint) was not significantly different between the ANG-3777 and placebo groups. There were no significant between-group differences in the duration of dialysis through day 30 or in the percentage of patients with eGFR >30 mL/min/1.73m

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Flavio Vincenti reports a relationship with eGenesis that includes: consulting or advisory. Flavio Vincenti reports a relationship with Eledon that includes: consulting or advisory. Flavio Vincenti reports a relationship with Merck that includes: consulting or advisory. Flavio Vincenti reports a relationship with Sanofi that includes: consulting or advisory. Flavio Vincenti reports a relationship with Veloxis that includes: consulting or advisory. Flavio Vincenti reports a relationship with Viela that includes: consulting or advisory. Jonathan Bromberg reports a relationship with CareDx that includes: consulting or advisory. Jonathan Bromberg reports a relationship with Eurofins that includes: consulting or advisory. Jonathan Bromberg reports a relationship with Natera that includes: consulting or advisory. Jonathan Bromberg reports a relationship with Pfizer that includes: consulting or advisory. Arman Faravardeh reports a relationship with Natera that includes: consulting or advisory. Arman Faravardeh reports a relationship with Veloxis that includes: consulting or advisory. Nicolae Leca reports a relationship with Angion Biomedica that includes: funding grants. Nicolae Leca reports a relationship with CareDx that includes: funding grants. Nicolae Leca reports a relationship with CSL Behring that includes: funding grants. Nicolae Leca reports a relationship with Hansa Pharmaceuticals that includes: funding grants. Nicolae Leca reports a relationship with Memo Therapeutics that includes: funding grants. Nicolae Leca reports a relationship with Natera that includes: funding grants. Nicolae Leca reports a relationship with Novartis that includes: funding grants. Nicolae Leca reports a relationship with Transplant Genomics that includes: funding grants. Nicolae Leca reports a relationship with Verici that includes: funding grants. Gabriela Alperovich reports a relationship with CSL Vifor that includes: employment and equity or stocks. Philipp Andreas Csomor reports a relationship with CSL Vifor that includes: employment and equity or stocks. Shakil Aslam reports a relationship with Angion Biomedica that includes: employment and equity or stocks at time of study. Shakil Aslam reports a relationship with BioCryst Pharmaceuticals, Inc. that includes: employment. John Neylan reports a relationship with Angion Biomedica that includes: employment and equity or stocks at time of study. John Neylan reports a relationship with Akari Therapeutics, Plc that includes: employment. The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation: Flavio Vincenti has research or consulting contracts with Egenesis, Eledon, Merck, Sanofi, Veloxis, and Viela/Horizon. Jonathan Bromberg has research or consulting contracts with CareDx, Eurofins/TGI, Natera, and Pfizer. Jim Kim has no conflicts of interest to disclose. Arman Faravardeh has research or consulting contracts with Natera and Veloxia. Nicolae Leca has received institutional funding for multicenter trials from Angion, CareDx, CSL Behring, Hansa Pharmaceuticals, Memo Therapeutics, Natera, Novartis, Transplant Genomics, and Verici. Gabriela Alperovich and Philipp Andreas Csomor are employees of, and hold equity in, CSL Vifor. Shakil Aslam and John Neylan were employees of, and held equity in, Angion Biomedica at the time of the study, and are current employees of BioCryst Pharmaceuticals, Inc. (Shakil Aslam) and Akari Therapeutics, Plc (John Neylan).